Legal & General Group Plc lowered its position in Aimmune Therapeutics, Inc. (NASDAQ:AIMT) by 1.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,142 shares of the biotechnology company’s stock after selling 96 shares during the period. Legal & General Group Plc’s holdings in Aimmune Therapeutics were worth $134,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. Teachers Advisors LLC increased its stake in shares of Aimmune Therapeutics by 2.6% in the first quarter. Teachers Advisors LLC now owns 44,349 shares of the biotechnology company’s stock worth $964,000 after buying an additional 1,120 shares during the period. Wellington Management Group LLP increased its stake in Aimmune Therapeutics by 641.2% in the first quarter. Wellington Management Group LLP now owns 2,316,553 shares of the biotechnology company’s stock worth $50,339,000 after buying an additional 2,004,023 shares during the last quarter. Alliancebernstein L.P. increased its stake in Aimmune Therapeutics by 4.9% in the first quarter. Alliancebernstein L.P. now owns 750,640 shares of the biotechnology company’s stock worth $16,311,000 after buying an additional 34,913 shares during the last quarter. American International Group Inc. increased its stake in Aimmune Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 16,184 shares of the biotechnology company’s stock worth $352,000 after buying an additional 1,070 shares during the last quarter. Finally, Victory Capital Management Inc. bought a new stake in Aimmune Therapeutics during the first quarter worth about $1,064,000. Institutional investors and hedge funds own 69.65% of the company’s stock.

Aimmune Therapeutics, Inc. (AIMT) traded up 0.76% during midday trading on Thursday, reaching $19.80. 5,334 shares of the company’s stock traded hands. Aimmune Therapeutics, Inc. has a 52 week low of $12.38 and a 52 week high of $27.31. The stock’s market capitalization is $1.00 billion. The company’s 50-day moving average price is $20.86 and its 200 day moving average price is $20.00.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.64) by $0.01. On average, equities research analysts expect that Aimmune Therapeutics, Inc. will post ($2.71) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This story was first posted by Daily Political and is the property of of Daily Political. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at https://www.dailypolitical.com/2017/08/17/legal-general-group-plc-sells-96-shares-of-aimmune-therapeutics-inc-aimt.html.

AIMT has been the subject of a number of recent analyst reports. Zacks Investment Research downgraded shares of Aimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. Piper Jaffray Companies set a $38.00 target price on shares of Aimmune Therapeutics and gave the company a “buy” rating in a report on Thursday, July 27th. ValuEngine downgraded shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 27th. Wedbush restated an “ourperform” rating and issued a $42.00 target price on shares of Aimmune Therapeutics in a report on Monday. Finally, BidaskClub downgraded shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $33.00.

In related news, insider Stephen George Dilly sold 50,000 shares of the firm’s stock in a transaction on Wednesday, July 26th. The stock was sold at an average price of $21.46, for a total value of $1,073,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Susan E. Barrowcliffe sold 6,110 shares of the firm’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $22.00, for a total value of $134,420.00. Following the completion of the transaction, the insider now directly owns 960 shares of the company’s stock, valued at $21,120. The disclosure for this sale can be found here. Insiders sold 188,470 shares of company stock valued at $3,942,092 over the last three months. 24.56% of the stock is owned by company insiders.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Want to see what other hedge funds are holding AIMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aimmune Therapeutics, Inc. (NASDAQ:AIMT).

Institutional Ownership by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.